9 AbbVie Executives Awarded Stock Grants in Coordinated February Move
Nine AbbVie executives, including CEO Robert Michael and the company's entire C-suite, received stock awards on the same day — February 18, 2026 — in what appears to be a coordinated annual compensation event.
The Trades
The synchronized awards occurred on a single day, with all nine senior executives receiving grants at the same time. While the SEC filing shows the awards as having undefined values, this simultaneous timing is typical of annual equity compensation cycles at major pharmaceutical companies.
The executives receiving awards include:
- Robert A. Michael, Chief Executive Officer
- Scott T. Reents, EVP and Chief Financial Officer
- Roopal Thakkar, EVP of R&D and Chief Scientific Officer
- Jeffrey Ryan Stewart, EVP and Chief Commercial Officer
- Perry C. Siatis, EVP, General Counsel and Secretary
- Azita Saleki-Gerhardt, EVP and Chief Operations Officer
- Demetris D. Crum, EVP and Chief HR Officer
- Nicholas Donoghoe, EVP and Chief Business/Strategy Officer
- David Ryan Purdue, SVP and Controller
Who's Trading
The list represents AbbVie's complete senior leadership team, from the CEO down through key operational roles. This comprehensive inclusion suggests these awards are part of the company's standard executive compensation program rather than performance-based or discretionary grants.
Beyond the February cluster, the filing reveals additional director activity from late 2025. Board members Edward J. Rapp, Susan E. Quaggin, and Robert J. Alpern received smaller quarterly awards throughout Q3 and Q4 2025, ranging from 33 to 177 shares per grant. These director awards, valued between $7,400 and $33,500 each, followed AbbVie's typical quarterly director compensation schedule.
Notably, EVP Azita Saleki-Gerhardt exercised 42,370 options in August 2025 at $54.86 per share, representing over $2.3 million in option value. The exercise price of $54.86 compared to current trading levels above $180 suggests these were likely older grants with substantial built-in gains.
What to Watch
The simultaneous February 18 awards across all senior leadership positions indicate AbbVie is entering its annual equity grant cycle. These coordinated grants typically vest over multiple years and are designed to align executive interests with long-term shareholder value.
For context, AbbVie's stock has performed well over the past year, with shares trading above $180 in recent quarters compared to the $54.86 exercise price from older grants. This performance provides executives with substantial value in their existing equity holdings.
The timing of these awards — mid-February — aligns with many companies' annual compensation cycles following year-end performance reviews and board compensation committee meetings. Investors should expect detailed proxy disclosures in the coming months that will reveal the specific values and vesting terms of these grants.
The presence of all key executives in this single-day grant event, rather than staggered awards throughout the year, suggests strong retention focus and unified compensation philosophy at AbbVie's leadership level. This coordination is particularly notable given the pharmaceutical industry's competitive talent market and the company's position as one of the sector's largest players.
While the filing shows these as zero-cost awards (typical for restricted stock units), the actual value will depend on AbbVie's stock price at vesting. Given the company's current market capitalization of over $300 billion and its position in key therapeutic areas including immunology and oncology, these awards represent significant potential compensation tied directly to stock performance.
Investors monitoring insider activity should note that coordinated grant events like this are routine and don't necessarily signal insider sentiment about the stock. More telling are open-market purchases or sales outside of predetermined plans, neither of which appear in this cluster.